Health Catalyst Inc

Análisis de la acción Health Catalyst Inc (HCAT)

$1.500

-0.085 (-5.66%)Al cierre

Loading chart…
Máximo
1.590
Apertura
1.590
Precio medio ponderado por volumen
1.51
Volumen
336.35K
Capitalización
357.16M
Mínimo
1.450
Importe
509.00K
EV/EBITDA, TTM
6.09

Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The Company's solution comprises its cloud-based data platform, applications, and expertise. Its segments include Technology and Professional Services. The Technology segment includes its data platform, analytics applications and support services and earns primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees. The Professional Services segment is generally a combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver capabilities to its clients to fully configure and utilize the benefits of its technology offerings. Its clients, which are primarily healthcare providers, use its Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements.

Análisis de IA of Health Catalyst Inc (HCAT)

Vender

Health Catalyst Inc is not a good buy right now. The current price is $1.58, which is significantly below the 52-week high of $3.36, indicating a decline of 53.0%. Additionally, the RSI is at 34.34, suggesting that the stock is oversold. The company has reported substantial losses, with a net income of -$111 million in Q1 2026 and -$40.5 million in Q2 2026, which raises concerns about its profitability. The main risk is the ongoing uncertainty around client churn and potential down-sell risks, as highlighted by analyst downgrades.

Métricas de valoración

El PER previsto actual de Health Catalyst Inc (HCAT) es 10.00, frente a su media de 5 años de -7.88.

PER previsto

Valor razonable
Media 5A P/E
-7.88
P/E actual
10.00
Sobrevalorada
103.22
Infravalorada
-118.99

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
-53.03
EV/EBITDA actual
6.09
Sobrevalorada
98.36
Infravalorada
-204.42

Precio/ventas previsto

Valor razonable
Media 5A P/S
1.83
P/S actual
0.58
Sobrevalorada
3.43
Infravalorada
0.24

Escenarios de precio de Alphio AI para HCAT

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%HCAT

$4.94

Precio del escenario

B

Base

Base · 50%HCAT

$4.25

Precio del escenario

B

Bajista

Bajista · 25%HCAT

$4.22

Precio del escenario

Ballenas con HCAT en cartera

F

First Light Asset Management, LLC

+ Con en carteraHCAT

+0.00%

Rentabilidad a 3 meses

Cronología de eventos

2026-09-08 (ET)

09:00:00

Health Catalyst Appoints Simeon Kohl as CEO

2026-08-06 (ET)

17:30:00

Health Catalyst Closes Sale of Vitalware for $147 Million

17:00:00

Company Reports Q2 Revenue of $70.49M, Exceeding Expectations

17:00:00

Sees FY26 Adjusted EBITDA of $18M to $18.5M

17:00:00

Sees Q3 Adjusted EBITDA of $0-$500K

Noticias

Preguntas frecuentes sobre HCAT, respondidas por Alphio AI

Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The Company's solution comprises its cloud-based data platform, applications, and expertise. Its segments include Technology and Professional Services. The Technology segment includes its data platform, analytics applications and support services and earns primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees. The Professional Services segment is generally a combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver capabilities to its clients to fully configure and utilize the benefits of its technology offerings. Its clients, which are primarily healthcare providers, use its Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements. It operates in the Technology sector (SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ET industry).

Health Catalyst Inc is not a good buy right now. The current price is $1.58, which is significantly below the 52-week high of $3.36, indicating a decline of 53.0%. Additionally, the RSI is at 34.34, suggesting that the stock is oversold. The company has reported substantial losses, with a net income of -$111 million in Q1 2026 and -$40.5 million in Q2 2026, which raises concerns about its profitability. The main risk is the ongoing uncertainty around client churn and potential down-sell risks, as highlighted by analyst downgrades.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar